BridgeLine · Tools · Portfolio · Program Valuation
Program Valuation Calculator (rNPV)
Estimate your drug program's risk-adjusted net present value using phase-gated probability of success, development costs, revenue projections, and modality-specific benchmarks
Beta Testing. This tool is under active development. Results are estimates based on industry benchmarks and should not substitute for professional financial or strategic advice. We welcome feedback at info@bridgelinetranslational.com.
Modality & Benchmarks
Phase transition probabilities and development costs pre-loaded from industry data. Edit any value below.
Industry-average PoS and costs. Source: BIO/Informa/QLS clinical development success rates 2011-2023.
Development Phases
| Phase | Cost ($) | Duration (yr) | PoS (%) | Cum. PoS |
|---|---|---|---|---|
| Preclinical | 45% | 45.0% | ||
| Phase 1 | 52% | 23.4% | ||
| Phase 2 | 28% | 6.6% | ||
| Phase 3 | 57% | 3.7% | ||
| Filing & Approval | 90% | 3.4% |
Revenue & Discount Assumptions
Risk-adjusted net present value
Through approval (5 phases)
Probability-weighted
Probability-weighted dev costs
Value Waterfall
Phase-by-Phase Value Attribution
| Phase | Cost | PoS | Cum. PoS | PV Cost | PV Revenue | Net |
|---|---|---|---|---|---|---|
| Preclinical | $10.0M | 45% | 45.0% | $8.9M | - | -$8.9M |
| Phase 1 | $20.0M | 52% | 23.4% | $6.6M | - | -$6.6M |
| Phase 2 | $40.0M | 28% | 6.6% | $5.5M | - | -$5.5M |
| Phase 3 | $150.0M | 57% | 3.7% | $4.2M | - | -$4.2M |
| Filing & Approval | $5.0M | 90% | 3.4% | $64K | $26.8M | $26.7M |
| Total rNPV | $225.0M | 3.4% | $25.2M | $26.8M | $1.5M | |
Sensitivity Analysis
Impact on rNPV from varying key assumptions. Base rNPV: $1.5M.
What This Means
While the rNPV is positive ($1.5M), the cumulative PoS of 3.4% means success is a low-probability event. This is typical for early-stage programs. Investors will scrutinize each phase transition probability and look for de-risking milestones.
rNPV is widely used in pharma/biotech for program valuation and portfolio decisions. Pre-revenue biotech companies typically trade at 1-3x rNPV depending on management quality, IP, and competitive position.
Methodology & assumptions
rNPV = risk-adjusted net present value. Each future cash flow (cost or revenue) is weighted by the cumulative probability of reaching that point and discounted to present value.
Phase PoS benchmarks are from BIO/Informa/QLS analysis of clinical development success rates (2011-2023) and Nature Reviews Drug Discovery meta-analyses, stratified by modality.
Revenue projection uses a logistic S-curve ramp from launch to peak sales, flat through patent expiry, then annual erosion post-LOE.
WACC/Discount rate for preclinical biotech typically ranges 12-18%, reflecting high risk. Clinical-stage companies may use 10-14%.
Development costs include direct trial costs but not overhead, commercial launch, or manufacturing scale-up costs.
This tool provides estimates for planning purposes only and does not constitute financial, investment, or legal advice. Phase transition probabilities are industry averages; individual program risk profiles may differ significantly. Consult qualified professionals for valuation and investment decisions.
Sources & references
- Clinical success rates: Wong CH, Siah KW, Lo AW. Estimation of clinical trial success rates and related parameters. Biostatistics. 2019;20(2):273-286.
- Phase transition data: BIO/Informa/QLS Clinical Development Success Rates 2011-2020
- Drug development costs: Wouters OJ, McKee M, Luyten J. Estimated Research and Development Investment Needed to Bring a New Medicine to Market. JAMA. 2020;323(9):844-853.
- R&D productivity: Paul SM, Mytelka DS, Dunwiddie CT, et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat Rev Drug Discov. 2010;9(3):203-214.
- Biotech valuation methodology: Bogdan B, Villiger R. Getting real about valuations in biotech. Nat Biotechnol. 2005;23(4):423-428.
Continue your analysis by handing off to the next tool in the workflow. Your program data carries forward automatically.
BridgeLine · V8.0 Offer
Diligence Readiness Package
Independent narrative review, data room structure, one-pager, and anticipated questions register for investor and pharma BD diligence.
Price
$12,500
$18,000 expedited
Price
$12,500 standard / $18,000 expedited
Timeline
Standard delivery or Expedited (half timeline)
Fixed-fee scope. Deliverable: diligence-grade investor/partner package.
Book a Strategy Call§ / Engage
Your Valuation Model Needs a Matching Development Plan.
Your $1.5M rNPV estimate needs a development plan investors can underwrite. Book a complimentary Strategy Call to align your preclinical milestones with the valuation story and build diligence-ready materials.